ustekinumab
Selected indexed studies
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. (Lancet, 2018) [PMID:30097359]
- AVT04: An Ustekinumab Biosimilar. (Clin Drug Investig, 2024) [PMID:38963659]
- Ustekinumab for treating ulcerative colitis: an expert opinion. (Expert Opin Biol Ther, 2020) [PMID:32662683]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. (2018) pubmed
- AVT04: An Ustekinumab Biosimilar. (2024) pubmed
- Ustekinumab for treating ulcerative colitis: an expert opinion. (2020) pubmed
- Off-label uses of ustekinumab. (2022) pubmed
- [Ustekinumab - Current position]. (2018) pubmed
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. (2015) pubmed
- Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm. (2022) pubmed
- Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. (2018) pubmed
- Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review. (2021) pubmed
- Ustekinumab for the treatment of Crohn's disease. (2016) pubmed